New Insights into Individualized Antimetastatic Therapy

90% of cancer patients die of cancer metastasis. However, currently cancer chemotherapies are mainly focusing anticancer drugs targeting primary tumor instead of metastatic foci. So although the primary tumors have been inhibited by antiproliferative drugs, patient’s survival has been increased very little. If we shall change our focus on development of effective antimetastatic drugs and pursue of individualized cancer chemotherapy targeting metastatic pathogenesis stages. Thus we might expect enhancing patients’ survival by individualized antimetastatic therapies in future [1,2]. Now there seems basically no better option other than drugs for antimetastatic treatments, yet cancer metastasis treatment commonly does not work in most cases in clinics. Any small breakthrough for antimetastatic therapy will lead to great clinical achievements in cancer therapies [3]. Thus herein it is reiterated that more attentions should be paid to development of more effective antimetastatic drugs and treatment of neoplasm metastases according to clinical circumstance of patients. In order to achieve this goal, we address individualized antimetastatic therapy by targeting different metastatic cascade and drugs targeting at formed metastatic foci.